Works matching AU Ailawadhi, Sikander
Results: 142
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01206-4
- By:
- Publication type:
- Article
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01177-6
- By:
- Publication type:
- Article
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
- Published in:
- 2024
- By:
- Publication type:
- Letter
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01129-0
- By:
- Publication type:
- Article
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01081-z
- By:
- Publication type:
- Article
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01067-x
- By:
- Publication type:
- Article
Global disparities in patients with multiple myeloma: a rapid evidence assessment.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00877-9
- By:
- Publication type:
- Article
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00820-y
- By:
- Publication type:
- Article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00805-x
- By:
- Publication type:
- Article
Prognostic value of early bone marrow MRD status in CAR-T therapy for myeloma.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00820-y
- By:
- Publication type:
- Article
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
- Published in:
- 2023
- By:
- Publication type:
- Letter
Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 11, p. 1, doi. 10.1038/s41408-022-00752-z
- By:
- Publication type:
- Article
Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00725-2
- By:
- Publication type:
- Article
Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 9, p. 1, doi. 10.1038/s41408-022-00721-6
- By:
- Publication type:
- Article
Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 6, p. 1, doi. 10.1038/s41408-022-00680-y
- By:
- Publication type:
- Article
Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis.
- Published in:
- Blood Cancer Journal, 2022, v. 12, n. 3, p. 1, doi. 10.1038/s41408-022-00638-0
- By:
- Publication type:
- Article
Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect<sup>®</sup> MM Registry.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 10, p. N.PAG, doi. 10.1038/s41408-019-0237-1
- By:
- Publication type:
- Article
Whole Exome Sequencing Leading to the Diagnosis of Dysferlinopathy with a Novel Missense Mutation (c.959G>C).
- Published in:
- Case Reports in Genetics, 2016, p. 1, doi. 10.1155/2016/9280812
- By:
- Publication type:
- Article
Characteristics and Treatment Patterns of Long-surviving Patients With Multiple Myeloma: Over 13 Years of Follow-up in the Connect® MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2025, v. 25, n. 12, p. 58, doi. 10.1016/j.clml.2024.11.001
- By:
- Publication type:
- Article
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the Connect® MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 10, p. e336, doi. 10.1016/j.clml.2024.05.021
- By:
- Publication type:
- Article
Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 6, p. 358, doi. 10.1016/j.clml.2024.02.004
- By:
- Publication type:
- Article
Optimizing the CAR T-Cell Therapy Experience in Multiple Myeloma: Clinical Pearls From an Expert Roundtable.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 5, p. e217, doi. 10.1016/j.clml.2024.01.014
- By:
- Publication type:
- Article
Treatment Patterns, Survival, Quality of Life, and Healthcare Resource Use Among Patients With Triple-Class Refractory Multiple Myeloma in US Clinical Practice: Findings From the Connect MM Disease Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 2, p. 112, doi. 10.1016/j.clml.2022.11.008
- By:
- Publication type:
- Article
Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 3, p. 149, doi. 10.1016/j.clml.2021.08.007
- By:
- Publication type:
- Article
P-136: Health-related quality of life (HRQL) among real-world Ide-Cel–eligible patients (pts) with relapsed/refractory Multiple Myeloma (RRMM): results from the Connect® MM registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S109, doi. 10.1016/S2152-2650(21)02263-1
- By:
- Publication type:
- Article
MM-200: A Qualitative Study of Patients' Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S428, doi. 10.1016/S2152-2650(21)01955-8
- By:
- Publication type:
- Article
IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S401, doi. 10.1016/S2152-2650(21)01906-6
- By:
- Publication type:
- Article
Poster: MM-200: A Qualitative Study of Patients' Preferences for the Treatment of Relapsed or Refractory Multiple Myeloma (RRMM) in the United States, United Kingdom, France, and Germany.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S255, doi. 10.1016/S2152-2650(21)01598-6
- By:
- Publication type:
- Article
Poster: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S244, doi. 10.1016/S2152-2650(21)01536-6
- By:
- Publication type:
- Article
Oral Abstract: IBCL-085: Assessment of Fixed-Duration Therapies for Treatment-Naïve Waldenström Macroglobulinemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01277-5
- By:
- Publication type:
- Article
Efficacy of Daratumumab-Based Regimens for the Treatment of Plasma Cell Leukemia.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. 355, doi. 10.1016/j.clml.2021.01.002
- By:
- Publication type:
- Article
Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 5, p. e449, doi. 10.1016/j.clml.2020.12.023
- By:
- Publication type:
- Article
Treatment Journeys of Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The Connect MM Registry.
- Published in:
- 2020
- By:
- Publication type:
- journal article
CLR 131 Demonstrates High Rate of Activity in a Phase 1, Dose Escalation Study in Patients with Relapsed or Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e356, doi. 10.1016/j.clml.2019.09.589
- By:
- Publication type:
- Article
Carfilzomib-based induction improves progression free survival and rate of minimal residual disease negativity following autologous transplant in high risk multiple myeloma patients: a retrospective analysis.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e217, doi. 10.1016/j.clml.2019.09.361
- By:
- Publication type:
- Article
Frequency of and Associations Amongst Baseline Cytogenetics in Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e75, doi. 10.1016/j.clml.2019.09.119
- By:
- Publication type:
- Article
Effect of t(11;14) on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect® MM Registry.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e74, doi. 10.1016/j.clml.2019.09.118
- By:
- Publication type:
- Article
Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Single-Center Experience of Axicabtagene Ciloleucel CAR-T Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. S267, doi. 10.1016/j.clml.2019.07.191
- By:
- Publication type:
- Article
Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Role of Proteasome Inhibitors in Relapsed and/or Refractory Multiple Myeloma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Trends in the Risks of Secondary Cancers in Patients With Hodgkin Lymphoma.
- Published in:
- 2018
- By:
- Publication type:
- journal article
ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S314, doi. 10.1016/j.clml.2017.07.115
- By:
- Publication type:
- Article
Influence of Obesity on Outcomes of Patients with Relapsed Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e139, doi. 10.1016/j.clml.2017.03.252
- By:
- Publication type:
- Article
Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2016, v. 16, p. S64, doi. 10.1016/j.clml.2016.07.094
- By:
- Publication type:
- Article
Persistent Disparities Among Patients With T-Cell Non-Hodgkin Lymphomas and B-Cell Diffuse Large Cell Lymphomas Over 40 Years: A SEER Database Review.
- Published in:
- 2015
- By:
- Publication type:
- journal article